Kahn Swick & Foti, LLC ("KSF") and KSF partner Former Attorney General of Louisiana, Charles C. Foti, Jr. announce that the firm continues its investigation in the firm’s securities class action lawsuit against SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (Nasdaq: SCLN – News), filed in the United States District Court for the Northern District of California, on behalf of purchasers of the common stock of the Company between May 11, 2009 and August 10, 2010, inclusive (the “Class Period”). No class has yet been certified in this action. What You May Do If you have information that would assist KSF in its ongoing investigation prior to the filing of a consolidated amended complaint in court on November 29, 2010, or would like to discuss your legal rights, you may, without obligation or cost to you, call or e-mail KSF Managing Partner, Lewis Kahn ( firstname.lastname@example.org), toll free 1-866-467-1400, ext. 200, or after hours via cell phone 504-301-7900. KSF encourages anyone with information regarding SciClone’s conduct during the period in question to contact the firm to discuss the investigation, including whistleblowers, former employees, shareholders and others. KSF attorneys have significant experience in representing both institutional and individual shareholders in securities fraud litigation nationwide. About the Lawsuit SciClone and certain of its Officers are charged with making a series of materially false and misleading statements related to the Company’s business and operations in violation of the Securities Exchange Act of 1934. SciClone engaged in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in the People’s Republic of China and internationally. Its principal product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems. Throughout the Class Period, SciClone claimed to have commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam.